← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Virogenomics Biodevelopment, Inc.
Tigard, OR
$9,751,063
Total funding
10
Grants
Funding over time
peak $3.3M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,751,063 · 10
By mechanism
UG3$3,287,052 · 1
R44$2,991,622 · 1
R41$1,453,762 · 5
R42$1,450,053 · 1
R43$568,574 · 2
Investigators at Virogenomics Biodevelopment, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
IND-enabling studies and phase I clinical trials to advance CD74-target, DRhQ, as a treatment for stimulant use disorder$3,287,052
UG3 · FY2025 · DA
Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects$998,210
R44 · FY2020 · AI
Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects$996,926
R44 · FY2021 · AI
Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects$996,486
R44 · FY2022 · AI
Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects$747,347
R42 · FY2018 · AI
Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects$702,706
R42 · FY2017 · AI
Immunotherapeutic Targeting CD74 as a Treatment for Stimulant Use Disorder$405,334
R41 · FY2024 · DA
Sensitive Single Cell PhosphoCount Platform for Drug-Insensitive Cell Detection and Combination Drug Screening for Leukemia$299,931
R43 · FY2016 · CA
DRα1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder$299,560
R41 · FY2019 · DA
DRα1-MOG: A Novel Immunomodulatory Therapeutic for Stroke$299,186
R41 · FY2017 · NS
Developing novel fibrillin biomarkers for aortic disease$268,643
R43 · FY2019 · HL
Preclinical and neuroimmunologic study of RTL1000 for methamphetamine addiction$224,886
R41 · FY2015 · DA
Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects$224,796
R41 · FY2016 · AI